˾Ī˾͡,Semustine
1)Semustine˾Ī˾͡
Ó¢ÎĶ̾ä/Àý¾ä

1.Preparation of semustine polyvinylpyrrolidone magnetic liposome˾Ī˾͡¾ÛÒÒÏ©ßÁ¿©Íéͪ´ÅÐÔÖ¬ÖÊÌåµÄÖƱ¸
2.HPLC assay for the related substances of carmustineHPLC·¨²â¶¨¿¨ÄªË¾Í¡×¢ÉäÒºµÄº¬Á¿
3.Study on Controlled Release of Anticancer-drug Lomustine & Vincristine;¿¹Ö×ÁöÒ©ÎïÂåĪ˾͡¡¢³¤´ºÐ¼î¿ØÖÆÊͷŵÄÑо¿
4.Studies on Iohexol Specified Lomustine Thermo-Sensitive Liposomes;µâº£´¼¶¨Î»ÂåĪ˾͡ζÈÃô¸ÐÖ¬ÖÊÌåµÄÑо¿
5.Studies of C6 Glioma Cells Apoptosis Induced by Carmustine and Its Mechanism;¿¨ÄªË¾Í¡¶Ô½ºÖÊÁöϸ°ûµòÍö×÷ÓõÄʵÑéÑо¿
6.The Empirical Study of Chemotherapy with Nimustine Plus Cisplatin for C6 GliomaÄáĪ˾͡ÁªºÏ˳²¬ÖÎÁÆC6ÄÔ½ºÖÊÁöµÄʵÑéÑо¿
7.Preparation and Tissue Distribution of Carmustine Liposomes in Mice¿¨ÄªË¾Í¡Ö¬ÖÊÌåµÄÖƱ¸¼°ÆäÔÚСÊóÌåÄڵķֲ¼
8.Preparation and characteristics of BCUN- loaded lipid ultrasound contrast agentÔØ¿¨ÄªË¾Í¡Ö¬Öʳ¬ÉùÔìÓ°¼ÁÖƱ¸¼°ÌØÐÔµÄÑо¿
9.Determination of bendamustine hydrochloride and related substance by HPLCHPLC·¨²â¶¨ÑÎËá±½´ïĪ˾͡º¬Á¿¼°ÓйØÎïÖÊ
10.Studies on Rats Model of Disorders of Cortical Development Induced by Carmustine and Related Neurotransmitters;¿¨ÄªË¾Í¡ÓÕµ¼´óÊóƤÖÊ·¢ÓýÕÏ°­Ä£Ðͼ°Ïà¹ØÉñ¾­µÝÖÊÑо¿
11.Studies on the Effects and Mechanisms of Bendamustine in the Mice Mammarry Carcinoma Cells;±½´ïĪ˾͡£¨Bendamustine£©ÓÕµ¼Ð¡ÊóÈéÏÙ°©Ï¸°ûµòÍö¼°Æä»úÖƵÄÑо¿
12.BCNU Combined with VEGF Antibody for the Treatment of Malignant Glioma;¿¨ÄªË¾Í¡ºÍVEGF¿¹ÌåÁªºÏÓ¦ÓöÔC6½ºÖÊÁöÒÖÖÆ×÷ÓõĻúÖÆÑо¿
13.Nitric Oxide Suppresses Lomustine Cytotoxicity in BT-325 Glioma Cells;Ò»Ñõ»¯µªÒÖÖÆÂåĪ˾͡¶ÔBT-325½ºÖÊÁöϸ°ûµÄϸ°û¶¾×÷ÓÃ
14.The Study of Ultrasound Combined with BCNU-Loaded Lipid Microbubble to Treat Glioma of the Rats³¬ÉùÁªºÏÔØ¿¨ÄªË¾Í¡Ö¬ÖÊ΢ÅÝÖÎÁÆ´óÊóÄÔ½ºÖÊÁöµÄÑо¿
15.The role of cell apoptosis in glioma chemotherapy evaluationÌæÄá²´ÜÕºÍÂåĪ˾͡ÓÕµ¼ÄÔ½ºÖÊÁöϸ°ûµòÍöµÄ»úÖÆ
16.Determination of content and entrapment efficiency of lomustine-iohexol compound liposomes by HPLCHPLC·¨²â¶¨ÂåĪ˾͡-µâº£´¼¸´·½Ö¬ÖÊÌåµÄÒ©ÎﺬÁ¿¼°°ü·âÂÊ
17.Ultrasound combined Carmustine-loaded lipid microbubbles induced apoptosis in rat C6 glioma cells³¬ÉùÁªºÏÔØ¿¨ÄªË¾Í¡Ö¬ÖÊ΢ÅÝÓÕµ¼´óÊóC6ϸ°ûµòÍö
18.Pharmacokinetics of BCNU-PLA Delayed Release Wafer Embedded in Brain of Dogs¿¨ÄªË¾Í¡-¾ÛÈéËỺÊÍĤƬֲÈë¼ÒÈ®ÄÔÄÚµÄÒ©´ú¶¯Á¦Ñ§Ñо¿
Ïà¹Ø¶Ì¾ä/Àý¾ä

lomustineÂåĪ˾͡
1.Clinical effect of temozolomide vs teniposide and lomustine in patients with malignant glioma;µ¥ÓÃÌæĪßò°·ÓëÌæÄá²´ß°ÁªºÏÂåĪ˾͡ÖÎÁƶñÐÔ½ºÖÊÁöµÄ±È½Ï
2.Synthesis of lomustine utilizing triphosgene;¹ÌÌå¹âÆø·¨ºÏ³ÉÂåĪ˾͡
3.Study on Controlled Release of Anticancer-drug Lomustine & Vincristine;¿¹Ö×ÁöÒ©ÎïÂåĪ˾͡¡¢³¤´ºÐ¼î¿ØÖÆÊͷŵÄÑо¿
3)Carmustine['k¨»:mjustain]¿¨ÄªË¾Í¡
1.Determination of Carmustine Injection by HPLC;HPLC·¨²â¶¨¿¨ÄªË¾Í¡×¢ÉäÒºµÄº¬Á¿
2.Preparation and characteristics of carmustine long-circulating thermosensitive liposomes;¿¨ÄªË¾Í¡³¤Ñ­»·ÈÈÃôÖ¬ÖÊÌåµÄÖƱ¸Óë±íÕ÷
4)BCNU¿¨ÄªË¾Í¡
1.In Vitro and In Vivo Release and Distribution of BCNU-PLA Microspheres;¿¨ÄªË¾Í¡¾ÛÈéËá΢ÇòµÄÌåÍâÊͷż°ÆäÔÚ´óÊóÄÔ×éÖ¯Öеķֲ¼Ñо¿
2.OBJECTIVE To prepare carmustine(BCNU)-loaded polylactic acid microspheres by spray dry method,and to study the effect of the process technologic on the morphology and drug release behavior.Ä¿µÄÒÔÅçÎí¸ÉÔï·¨ÖƱ¸¿¨ÄªË¾Í¡(carmustine,BCNU)-¾ÛÈéËỺÊÍ΢Çò,Ñо¿¹¤ÒÕÌõ¼þ¶Ô΢ÇòÐÎ̬¼°Ò©ÎïÊͷŵÄÓ°Ïì¡£
3.Objective: To study the inhibitory effects of stereotactic delivery of BCNU-loaded poly (lactic acid) microspheres (Tf-(BCNU-PLA) coated with transferrin against intracranial C6 gliomas.Ä¿µÄ:Ñо¿Á¢Ì嶨Ïò¾Ö²¿Í¶µÝÒÔתÌúµ°°×ÊÜÌåΪÅä»ùµÄ¾ÛÈéËỺÊÍ¿¨ÄªË¾Í¡(BCNU)[Tf-(BCNU¡ªPLA)]΢Çò¶ÔC6½ºÖÊÁöµÄÖÎÁÆЧ¹û¡£
5)fotemustine¸£ÄªË¾Í¡
1.Efficacy evaluation of fotemustine administered in adult patients with supratentorial malignant glioma;¸£ÄªË¾Í¡ÖÎÁƳÉÈËÄ»É϶ñÐÔ½ºÖÊÁöÁÆЧ¹Û²ì
2.Effect of fotemustine on the cell cycle of human glioma cell line U251;¸£ÄªË¾Í¡¶ÔÈËÄÔ½ºÖÊÁöϸ°ûÖêU251ϸ°ûÖÜÆÚµÄÓ°Ïì
3.Objective:To prepare polybutylcyanoacrylate(PBCA) nanocarriers with optimized process,double-located with Tween80 and(or) polyethylene glycol(PEG)20000,to further prepare fotemustine polybutylcyanoacrylate nanoparticles(FCNU-PBCA-NP) and temozolomide polybutylcyanoacrylate nanoparticles(TMZ-PBCA-NP).Ä¿µÄ:ÓÅ»¯¹¤ÒÕÖƱ¸ÍÂÎÂ80ºÍ(»ò)PEG20000Ë«ÖØÐÞÊεľÛÇè»ù±ûÏ©ËáÕý¶¡õ¥ÄÉÃ×ÔØÌå,½øÒ»²½ÖƱ¸°üÔظ£ÄªË¾Í¡¡¢ÌæĪßò°·µÄ¾ÛÇè»ù±ûÏ©ËáÕý¶¡õ¥ÄÉÃ×Á£¡£
6)LumostineÂåĪ˾͡
1.Lumostine is given to the patients every 8 weeks.Ä¿µÄÙ¤Â굶ÁªºÏÂåĪ˾͡ÖÎÁÆÄÔתÒÆÁö,Ìá¸ßÁÆЧ¡£
2.Lumostine is given to the patients every next 8 weeks.½áÂÛ Ù¤Â굶ÁªºÏÂåĪ˾͡ÖÎÁÆÄÔתÒÆÁöÊÇÒ»ÖÖÓÐЧµÄ´ëÊ©£¬Ð§¹û½Ïµ¥´¿Ù¤Â굶¼Ñ¡£
ÑÓÉìÔĶÁ

˾Ī˾͡¡¾Í¨ÓÃÃû³Æ¡¿Ë¾ÄªË¾Í¡¡¾ÆäËûÃû³Æ¡¿Ë¾ÄªË¾Í¡ ˾Ī˾͡ Æ´ÒôÃû£ºSimositing Ó¢ÎÄÃû£ºSemustine ÊéÒ³ºÅ£º2000Äê°æ¶þ²¿£­201 C10H18ClN3O2 247.72 ±¾Æ·Îª1-(2-ÂÈÒÒ»ù)-3-(4-¼×»ù»µ¼º»ù)-1-ÑÇÏõëå¡£°´¸ÉÔïÆ·¼ÆË㣬º¬C10H18ClN3O2 ӦΪ97.0£¥¡«103.0 £¥¡£ ¡¾ÐÔ×´¡¿ ±¾Æ·Îªµ­»ÆÉ«ÂÔ´ø΢ºìÉ«µÄ½á¾§ÐÔ·ÛÄ©£¬¶Ô¹âÃô¸Ð¡£ ±¾Æ·ÔÚÂÈ·ÂÖм«Ò×Èܽ⣬ÔÚÒÒ´¼»ò»·¼ºÍéÖÐÈܽ⣬ÔÚË®Öм¸ºõ²»ÈÜ¡£ È۵㠱¾Æ·µÄÈ۵㣨¸½Â¼¢ö C£©Îª71¡«75¡æ¡£ ¡¾¼ø±ð¡¿ (1) È¡±¾Æ·Ô¼10mg£¬¼ÓÒÒ´¼5ml ÕñҡʹÈܽ⣬¼Ó1£¥»Ç°·Ï¡ÑÎËáÈÜÒº2 ml£¬ÖÃˮԡ¼ÓÈÈÔ¼10·ÖÖÓ£¬·ÅÀ䣬¼Ó¼îÐԦ£­ÝÁ·ÓÊÔÒº2ml£¬ÏԳȻÆÉ«¡£ (2) È¡º¬Á¿²â¶¨ÏîϵÄÈÜÒº£¬ÕÕ·Ö¹â¹â¶È·¨£¨¸½Â¼¢ô A£©²â¶¨£¬ÔÚ232nm µÄ²¨³¤´¦ ÓÐ×î´óÎüÊÕ¡£ (3)È¡±¾Æ·Ô¼10mg£¬¼ÓÇâÑõ»¯ÄÆÊÔÒº5ml,ÖÃˮԡ¼ÓÈÈ5 ·ÖÖÓ£¬ÏÔÂÈ»¯ÎïµÄ¼ø±ð·´Ó¦£¨¸½ ¼¢ó£©¡£ ¡¾¼ì²é¡¿ ÂÈ»¯Îï È¡±¾Æ·0.20g,¼ÓË®20ml£¬ÕñÒ¡£¬Â˹ý£¬ÂËÔüÓÃË®10mlÏ´µÓ£¬ºÏ ²¢Ï´ÒºÓëÂËÒº£¬ÒÀ·¨¼ì²é£¨¸½Â¼¢ø A£©£¬Óë±ê×¼ÂÈ»¯ÄÆÈÜÒº4.0ml ÖƳɵĶÔÕÕÒº±È½Ï£¬ ²»µÃ¸üŨ£¨0.02£¥£©¡£ ÓйØÎïÖÊ È¡±¾Æ·£¬¼ÓÒÒ´¼ÖƳÉÿ1ml Öк¬10mgµÄÈÜÒº£¬×÷Ϊ¹©ÊÔÆ·ÈÜÒº£»¾«ÃÜÁ¿ È¡ÊÊÁ¿£¬¼ÓÒÒ´¼Ï¡ÊͳÉÿ1mlÖк¬0.1mg µÄÈÜÒº£¬×÷Ϊ¶ÔÕÕÈÜÒº¡£ÕÕ±¡²ãÉ«Æ×·¨£¨¸½Â¼¢õ B£©ÊÔÑ飬ÎüÈ¡ÉÏÊöÁ½ÖÖÈÜÒº¸÷10¦Ìl £¬·Ö±ðµãÓÚͬһ¹è½º£È£Æ254±¡²ã°åÉÏ£¬ÒÔ»·¼ºÍé £­Âȷ£¨1:3£©ÎªÕ¹¿ª¼Á£¬Õ¹¿ªºó£¬ÁÀ¸É£¬ÖÃ×ÏÍâ¹âµÆ(254nm)ϼìÊÓ£¬¹©ÊÔÆ·ÈÜÒºÈçÏÔÔÓ Öʰߵ㣬Óë¶ÔÕÕÈÜÒºµÄÖ÷°ßµã±È½Ï£¬²»µÃ¸üÉî¡£ÔÙÖÃÓÚµâÕôÆøÖУ¬Ô­µã²»µÃÏÔ»ÆÉ«¡£ ¸ÉÔïʧÖØ È¡±¾Æ·£¬ÖÃÎåÑõ»¯¶þÁ׸ÉÔïÆ÷ÖУ¬¼õѹ¸ÉÔï4Сʱ£¬¼õʧÖØÁ¿²»µÃ¹ý0.5% £¨¸½Â¼¢ø L£©¡£ ³ã×ƲÐÔü ²»µÃ¹ý0.1£¥£¨¸½Â¼¢ø N£©¡£ ¡¾º¬Á¿²â¶¨¡¿ ±Ü¹â²Ù×÷¡£È¡±¾Æ·£¬¾«Ãܳƶ¨£¬¼Ó»·¼ºÍéÖƳÉÿ1mlÖÐÔ¼º¬20¦Ìg µÄÈÜÒº£¬ÕÕ·Ö¹â¹â¶È·¨£¨¸½Â¼¢ô A£©£¬ÔÚ232nm µÄ²¨³¤´¦²â¶¨ÎüÊնȣ¬°´C10H18ClN3O2 µÄÎüÊÕϵÊý£¨£Å1% 1cm£©Îª254¼ÆË㣬¼´µÃ¡£ ¡¾Àà±ð¡¿ ¿¹Ö×ÁöÒ©¡£ ¡¾Öü²Ø¡¿ Õڹ⣬Ãܷ⣬ÔÚÀä´¦±£´æ¡£ ¡¾ÖƼÁ¡¿ ˾Ī˾͡½ºÄÒ